Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Hydrochlorothiazide; Telmisartan
Consilient Health Ltd
C09DA07
Hydrochlorothiazide; Telmisartan
25mg ; 80mg
Tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: ; GTIN: 5391512452650
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT TOLUCOMBI 40 MG/12.5 MG TABLETS TOLUCOMBI 80 MG/12.5 MG TABLETS TOLUCOMBI 80 MG/25 MG TABLETS telmisartan/hydrochlorothiazide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Tolucombi is and what it is used for 2. What you need to know before you take Tolucombi 3. How to take Tolucombi 4. Possible side effects 5. How to store Tolucombi 6. Contents of the pack and other information 1. WHAT TOLUCOMBI IS AND WHAT IT IS USED FOR Tolucombi is a combination of two active substances, telmisartan and hydrochlorothiazide in one tablet. Both of these substances help to control high blood pressure. - Telmisartan belongs to a group of medicines called angiotensin II receptor antagonists. Angiotensin II is a substance produced in your body which causes your blood vessels to narrow thus increasing your blood pressure. Telmisartan blocks the effect of angiotensin II so that the blood vessels relax, and your blood pressure is lowered. - Hydrochlorothiazide belongs to a group of medicines called thiazide diuretics, which cause your urine output to increase, leading to a lowering of your blood pressure. High blood pressure, if not treated, can damage blood vessels in several organs, which could lead sometimes to heart attack, heart or kidney failure, stroke, or blindness. There are usually no symptoms of high blood pressure before damage occurs. Thus it is important to regularly measure blood pressure to verify if it is within the normal range. TOLUCOMBI (40 MG/12.5 MG Read the complete document
OBJECT 1 TOLUCOMBI 80 MG/25 MG TABLETS Summary of Product Characteristics Updated 20-May-2016 | Consilient Health Ltd 1. Name of the medicinal product Tolucombi 80 mg/25 mg tablets 2. Qualitative and quantitative composition Each tablet contains 80 mg telmisartan and 25 mg hydrochlorothiazide. Excipient(s) with known effect: Each tablet contains 114 mg of lactose (as monohydrate) and 294.08 mg sorbitol (E420). For the full list of excipients, see section 6.1. 3. Pharmaceutical form Tablet. 80 mg/25 mg tablets: White to yellowish white on one side and yellow marbled on the opposite side of two-layer biconvex oval tablet, tablet dimensions 18 mm x 9 mm. 4. Clinical particulars 4.1 Therapeutic indications Treatment of essential hypertension. Tolucombi fixed dose combination (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Tolucombi 80 mg/12.5 mg (80 mg telmisartan/12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately. 4.2 Posology and method of administration Posology Tolucombi should be taken in patients whose blood pressure is not adequately controlled by telmisartan alone. Individual dose titration with each of the two components is recommended before changing to the fixed dose combination. When clinically appropriate, direct change from monotherapy to the fixed combination may be considered. - Tolucombi 80 mg/25 mg may be administered once daily in patients whose blood pressure is not adequately controlled by Tolucombi 80 mg/12.5 mg or in patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately. Tolucombi is also available at the dose strengths 40 mg/12.5 mg and 80 mg/12.5 mg. _Special populations:_ Patients with renal impairment Periodic monitoring of renal function is advised (see section 4.4). Patients with hepatic impairment In patients with mild to moderate hepatic impairment the posology should not exceed Tolucombi Read the complete document